Khushalani on Building Upon the Benefit Achieved With Cemiplimab in CSCC

Nikhil Khushalani, MD, discusses cemiplimab-rwlc, which has become the preferred agent for the frontline treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma.

Read the full article here

Related Articles